Merck (NYSE:MRK) marked a major milestone in its bid to introduce a new formulation for its famous cancer therapy ...
Warren Buffett was a net seller of stocks for the eighth consecutive quarter in Q3. Berkshire initiated new positions in only ...
In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes the ...
Seeking Alpha on MSN1h
Incyte seesaws on report of potential Merck takeover interestIncyte (NASDAQ:INCY) shares seesawed and are now down 10% amid a posting about potential takeover speculation from Merck ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...
Merck & Co.'s board has raised the drugmaker's quarterly dividend by 5.2%, to 81 cents a share from 77 cents. The new payout, equal to $3.24 a year, represents an annual yield of about 3.37%, based on ...
The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback